Insite Vision Inc.  

(Public, OTCMKTS:INSV)   Watch this stock  
Find more results for 303, Inc
0.270
0.000 (0.00%)
Jul 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.26 - 0.27
52 week 0.10 - 0.35
Open 0.26
Vol / Avg. 12,500.00/230,747.00
Mkt cap 35.63M
P/E 11.99
Div/yield     -
EPS 0.02
Shares 131.95M
Beta 0.62
Inst. own 29%
Aug 4, 2014
Q2 2014 InSite Vision Incorporated Earnings Release (Estimated) Add to calendar
Jul 16, 2014
InSite Vision Incorporated Annual Shareholder Meeting - Webcast
May 14, 2014
Q1 2014 InSite Vision Incorporated Earnings Conference Call - Webcast
May 14, 2014
Q1 2014 InSite Vision Incorporated Earnings Release
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -405.81% 18.76%
Operating margin -301.13% 42.52%
EBITD margin - 42.87%
Return on average assets -146.71% 36.22%
Return on average equity - -
Employees 31 -
CDP Score - -

Address

965 ATLANTIC AVE
ALAMEDA, CA 94501
United States - Map
+1-510-8658800 (Phone)
+1-510-8655700 (Fax)

Website links

Description

InSite Vision Incorporated (InSite) is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company�s portfolio of products is based on its DuraSite sustained drug delivery technology. The Company has focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology, which include AzaSite, Besivance, AzaSite Plus, DexaSite, BromSit, DuraSite and ISV-101. AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin, a broad spectrum ocular antibiotic approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye).

Officers and directors

Timothy McInerney Independent Chairman of the Board
Age: 53
Timothy M. Ruane Chief Executive Officer, Director
Age: 48
Louis C. Drapeau CPA Chief Financial Officer, Vice President
Age: 70
Surendra Patel Vice President - Operations & Quality
Age: 57
Lyle M. Bowman Ph.D. Vice President - Development
Age: 64
Kamran Hosseini M.D., Ph.D. Chief Medical Officer, Vice President - Clinical & Regulatory Affairs
Age: 48
Brian Levy O.D. Independent Director
Age: 62
Robert O'Holla Independent Director
Age: 61
Craig A. Tooman Independent Director
Age: 48
Anthony J. Yost Independent Director
Age: 54